TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Mothaffar F RimawiPolly NiravathNicholas WangBrent N RexerAndres ForeroAntonio C WolffRita NandaAnna M StornioloIan KropMatthew P GoetzJulie R NangiaSao JiralerspongAnne PavlickJamunarani VeeraraghavanCarmine De AngelisCarolina GutierrezRachel SchiffSusan G HilsenbeckC Kent Osbornenull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Treatment with dual anti-HER2 therapy for 24 weeks led to a numeric increase in pCR rate in women with HER2-positive breast cancer, without using chemotherapy. If validated, this approach may help identify patients who may benefit from deescalation of therapy.
Keyphrases
- phase ii
- positive breast cancer
- locally advanced
- clinical trial
- open label
- rectal cancer
- phase iii
- gestational age
- placebo controlled
- squamous cell carcinoma
- radiation therapy
- lymph node
- epidermal growth factor receptor
- metastatic breast cancer
- stem cells
- chemotherapy induced
- tyrosine kinase
- preterm birth
- light emitting
- cell therapy